● Recruiting

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Condition: Relapsed/Refractory AL Amyloidosis · Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd.

PhasePhase 1

Planned participants9

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (9)

Research Site	Beijing, China	Recruiting
Research Site	Beijing, China	Recruiting
Research Site	Beijing, China	Recruiting
Research Site	Changchun, China	Recruiting
Research Site	Guangzhou, China	Recruiting
Research Site	Hangzhou, China	Not Yet Recruiting
Research Site	Suzhou, China	Recruiting
Research Site	Wenzhou, China	Recruiting
Research Site	Wuhan, China	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07250269